Pino MMM, Trejos HAM, Orozco OJM

Language: Spanish
References: 38
Page:
PDF size: 117.20 Kb.

ABSTRACT

Introduction: The progressive character of motor cognitive psychiatric behavioral functional symptoms of Huntington disease may cause deterioration in the perception of patients and their caregivers’ quality of life.
Objective: Describe quality of life related to health in patients suffering from Huntington disease, and in their caregivers who live in the Magdalena’s Department.
Methods: Cross-sectional descriptive study with comparison group, using a non-probabilistic intentional sampling. 87 patients with genetic test for the diagnosis, and first degree caregivers ranging in age from 19 to 88 years, suffering from Huntington disease were selected. The unified scale (UHDRS), (Huntington study group, 1996), and the quality of life scale WHOQOL-BREF, that assesses four aspects: physical health, psychological health, social relations and environment, were used. A descriptive analysis of data was carried out, and NOVA test was used to compare the groups.
Results: Statistically significant differences were found in reference to the perception of quality of life and satisfaction with health in the group of patients suffering from Huntington disease when compare to the group of caregivers (p=0,00), and the control group (p=0,00). The most affected aspects of patients’ quality of life were social relations and environment.
Conclusions: The study of quality of life provides a more understanding, comprehensive and valid assessment of patients and their relatives’ satisfaction with health and well-being due to the complexity of signs and symptoms of Huntington disease.

REFERENCES

1. Riley BE, Orr HT. Polyglutamine neurodegenerative diseases and regulation of transcription: assembling the puzzle. Genes Dev 2006; 20: 2183-92.

2. Folstein SE, Leigh RJ, Parhad IM, Folstein MF. The diagnosis of Huntington’s disease. Neurology 1986; 36: :1279-83.

3. Siemers E. Huntington disease. Arch Neurol 2001; 58: 30810.

4. Walker FO. Huntington's Disease. Seminars in neurology 2007; 27:143-50.

5. Bates G, Harper P, Jones L. The Epidemiology of Huntington's Disease. In: Harper PS, Eds. Huntington's Disease. London: Oxford University Press, 2002: 251 - 80.

6. Harper B. Huntington disease. J R Soc Med 2005; 98 (12): 550.

7. Kehoe P, Krawczak M, Harper PS, Owen M,Jones A. Age of onset in Huntington disease:sexspecific influence of apolipoprotein Egenotype and normal CAG repeat length. J MedGenet 1999; 36: 108-11.

8. Huntington´s Outreach Project for Education at Stanford. La enfermedad de Huntington en Sudamérica [Internet]. 2014, Jul. Disponible desde: http://web.stanford.edu/group/hopes/cgibin/ hopes_test/la-enfermedad-de-huntington-en-sudamerica/

9. Campo M. Fundación de Comunidades Vulnerables de Colombia [FUNCUVULC]. Enfermedad de Huntington casos encontrados. 2013. Disponible desde: https://fundacioncomunidadesvulnerablesdecolombia.wordpress.com/casosencontrados/

10. Comisión Europea. Dirección general de sanidad y protección de los consumidores. Consulta pública. Las enfermedades raras: un desafío para Europa. 2008, Feb Disponible desde: http://ec.europa.eu/health/ph_threats/non_com/docs/raredis_comm_es.pdf

11. Eurordis European. Rare diseases:understanding this public health priority. 2005. Disponible desde: http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf

12. Clare M. Eddy, Hugh E. Rickards Impact of cognitive and behavioural changes on quality of life in Huntington’s disease. Basal Ganglia 2013; 3:123-6.

13. Campbell MC, Stout JC, Finn PR. Reduced autonomic responsiveness to gambling task losses in HD. J Int Neuropsychological Soc 2004; 10(2):239-45.

14. Eddy CM, Rickards HE. Moral judgment and decision making in Huntington’sdisease. Basal Ganglia 2012; 2(3):139-42.

15. Montoya A, Price BH, Menear M, LePage M. Brain imaging and cognitive dysfunctions in Huntington’s disease. J Psychiatry Neurosci 2006; 31(1):21-9.

16. Craufurd D, Thompson JC, Snowden JS. Behavioural changes in Huntington’sdisease. Neuropsychiatry Neuropsychol Behav Neurol 2001; 14:219-26.

17. Paulsen JS, Ready RE, Hamilton JM, Mega MS, Cummings JL. Neuropsychiatricaspects of Huntington’s disease. J Neurol Neurosurg Psychiatry 2001;71: 310-4.

18. Helder DI, Kaptein AA, van Kempen GMJ, van Houwelingen JC, Roos RAC.Impact of Huntington’s disease on quality of life. Mov Disord 2001; 16:325-30.

19. Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality oflife in Huntington’s disease: which factors matter most? Mov Disord2004;24(4):574-8.

20. Ready RE, Mathews M, Leserman A, Paulsen JS. Patient and caregiver quality oflife in Huntington’s disease. Mov Disord 2008; 23(5):721-6.

21. Mitchell AJ, Kemp S, Benito-Leon J, Reuber M. The influence of cognitive impairment on health-related quality of life in neurological disease. ActaNeuropsychiatry 2010;22:2–13.

22. Roscoe LA, Corsentino E, Watkins S, McCall M, Sanchez-Ramos J. Well-being of family caregivers of persons with late-stage Huntington’s disease: lessons in stress and coping. Health Commun. 2009; 24(3): 239-48.

23. Williams JK, Hamilton R, Nehl C, McGonigal-Kenney M, Schutte DL, Sparbel K. et al. “No one else sees the difference”: ‘family members’ perceptions of changes in persons with preclinical Huntington disease. Am. J. Med. Genet. Part B. 2007; 144B(5): 636-641.

24. Williams JK, Skirton H, Paulsen JS, Tripp-Reimer T, Jarmon L, McGonigal KM. et al. The emotional experiences of family carers in Huntington disease. J. Adv. Nurs. 2009; 65(4): 789- 98.

25. Sparbel KJH, Driessnack M, Williams JK, Schutte DL, Tripp-Reimer T, McGonigal-Kenney M. et al. Experiences of teens living in the shadow of Huntington disease. J. Genet. Couns. 2008; 17(4): 327-335.

26. Espinosa O. Apuntes sobre calidad de vida, desarrollosostenible y sociedad de consumo: una mirada desdeAmérica Latina. Rev Contribuciones (Fundación KonradAdenauer de Alemania y el ciedla). 1999; 63(3):119-48.

27. Andrews FM, Withey SB. Social Indicators of Well-Being: Americans Perceptions of Life Quality. Nueva York: Plenum PRESS; 1976.

28. Hernández R, Fernández C, Baptista P. Metodología de la Investigación. 6a ed. México: McGraw-Hill; 2014.

29. Huntigton Study Group. Unified Huntington’s disease rating scale: reliability and consistency. Mov Disord 1996; 11:136-42.

30. WHOQOL-BREF Introduction, administration, scoring and version of the assessment. World Health Organization, Geneva 1996.

31. WHOQOL GROUP The development of the World Health Organization quality of life assessment instrument (the WHOQOL). In: Orley J. Kuyken W, editors. Quality of life assessment: international perspectives. Heidelberg: Springer Verlag; 1994.

32. Freire M, Ábalos GM, Olmedo M, Ramírez J,Fernández AM, Villaverde C. Estudio comparativo de los instrumentos WHOQOL-BREF y SF-36, para medir calidad de vida en mayores. Scientia 2008; 13:35-51.

33. Espinoza I, Osorio P, Torrejón MJ, Lucas-Carrasco R, Bunout D. Validación del cuestionario de calidadde vida (WHOQOL-BREF) en adultos mayores chilenos. Rev Med Chile 2011; 139: 579- 86.

34. Fernandez M, Grau C, Trigo P. Impacto de la enfermedad de Huntington en la familia. An. Sist. Sanit. Navar. 2012; 35(2):295-307.

35. Sobel SK, Cowan DB. Impact of genetic testing for Huntington disease on the family system.Am J Med Genet 2000; 90:49-59.

36. Sobel SK, Cowan DB. The Process of FamilyReconstruction after DNA Testing for Huntington Disease. J Genet Couns 2000; 9:237-51.

37. Sánches E. Una propuesta de orientación para familiares de pacientes con la enfermedad de Huntington. Rev Iberoamericana de Enfermería Comunitaria 2015; 8(2).

38. Duisterhof M, Trijsburg RW, Niermeijer MF,Roos R, Tibben A. Psychological studies in Huntington’s disease: Making up the balance. J Med Genet 2001; 38: 852-61.